Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Chief Financial Officer
On January 4, 2021, Checkmate Pharmaceuticals, Inc. (the "Company") appointed
Robert Dolski as Chief Financial Officer. Mr. Dolski will also serve as the
Company's principal financial officer and principal accounting officer.
Pursuant to an employment agreement, dated January 4, 2021, entered into between
the Company and Mr. Dolski (the "Employment Agreement"), Mr. Dolski will be paid
an annual base salary of $385,000 and will be eligible to receive an annual
performance-based bonus equal to 40% of his base salary. In connection with his
appointment, Mr. Dolski will receive a one time sign-on bonus of $45,000 and
will be granted a stock option to purchase 150,000 shares of the Company's
common stock (the "Equity Award"). The Equity Award will vest over four years,
with 25% vesting upon the first anniversary of Mr. Dolski's start date, and the
remainder vesting in equal installments over the following thirty-six
(36) months, beginning on January 4, 2021. The foregoing description of the
Employment Agreement does not purport to be complete and is qualified in its
entirety by the text of the Employment Agreement, a copy of which is filed as
Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by
reference.
Prior to joining the Company, Mr. Dolski, age 50, served as Vice President,
Finance, for Akcea Therapeutics, Inc. From June 2016 to May 2019, Mr. Dolski was
Vice President, Head of Financial Planning and Analysis at Moderna, Inc. and
from December 2013 to June 2016, Mr. Dolski was Senior Director, Finance at
Forum Pharmaceuticals Inc. In addition, from January 2013 to November 2013,
Mr. Dolski was an independent finance consultant to multiple healthcare,
start-up companies, and from April 2007 to December 2012, Mr. Dolski was with
Human Genome Sciences Inc., serving in various leadership roles, including as
Vice President, Finance and Treasury, where he helped build the financial
planning and analysis function.
There are no arrangements or understandings between Mr. Dolski and any other
person pursuant to which he was appointed as an executive officer of the
Company, and there are no relationships between Mr. Dolski and the Company that
would require disclosure under Item 404(a) of Regulation S-K.
Item 8.01. Other Events.
On January 4, 2021, the Company issued a press release announcing the
appointment of Mr. Dolski as Chief Financial Officer. A copy of the Company's
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.
Item 9.01. Exhibits
(d) Exhibits
10.1 Executive Employment Agreement, dated January 4, 2021, by and between
the Company and Robert Dolski.
99.1 Press Release issued by the Company on January 4, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
CHECKMATE PHARMACEUTICALS, INC. 
